Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
All news
Pharmaceutical
Research from IQVIA shows that the use of medicines in the USA is slowing, with growth down to 5% in 2022, reaching a total value of $429 billion on a net price basis. 3 May 2023
Pharmaceutical
The US Food and Drug Administration announced yesterday it is taking additional steps to support the use of decentralized clinical trials (DCTs) for drugs, biologics and devices, where some or all the trial-related activities occur at locations other than traditional clinical trial sites. 3 May 2023
Pharmaceutical
The Franco-Israeli partnership of MedinCell and Teva Pharmaceutical Industries has announced today that the US Food and Drug Administration (FDA) has approved Uzedy (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. 2 May 2023
Pharmaceutical
Despite a strong opening, New York-based pharma giant Pfizer saw its shares fall in price over the morning on Tuesday, following the release of its financial results for the first quarter of 2023. 2 May 2023
Biotechnology
US healthcare giant Johnson & Johnson’s Janssen Biotech subsidiary has entered into a worldwide collaboration and license agreement with China-based Cellular Biomedicine Group to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. 2 May 2023
Biotechnology
Breyanzi works in broadest array of B-cell malignancies of any CD19-directed CAR-T therapy, says BMS
Bristol Myers Squibb has announced positive top-line results from two studies on Breyanzi (lisocabtagene maraleucel), its CD19-directed CAR-T cell therapy. 2 May 2023
Biotechnology
Shares of Danish biotech Ascendis Pharma leapt, despite the company revealing that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with hypoparathyroidism. 2 May 2023
Biotechnology
Spanish skincare specialist Almirall has announced results from a new secondary analysis using data from the Phase III ADvocate and ADhere studies of lebrikizumab. 2 May 2023
Biotechnology
Maze Therapeutics, a privately-held Californian company translating genetic insights into new precision medicines, has announced the signing of an exclusive worldwide license agreement with French pharma major Sanofi. 2 May 2023
Biotechnology
Shares of New Jersey, USA-based biotech firm Iveric Bio closed up nearly 16% at $38.05 yesterday, on the news of an agreed takeover bid from Japanese pharma major Astellas Pharma, with the latter rising 2.2% to 2,093 yen. 2 May 2023
Biotechnology
USA-based Nanoscope Therapeutics, a biotech developing gene therapies for retinal degenerative diseases, has presented results from the Phase IIb RESTORE trial of MCO-010 for the treatment of retinitis pigmentosa at the ARVO Annual Meeting. 2 May 2023
Pharmaceutical
A 12% jump in the stock price of Avadel Pharmaceuticals on Monday reflects market confidence in the firm’s newly-approved cataplexy med Lumryz (sodium oxybate). 2 May 2023
Biotechnology
Swedish contract development and manufacturing organization (CDMO) today announced that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US Food and Drug Administration (FDA) as a manufacturing site of VOWST (fecal microbiota spores). 2 May 2023
Generics
Two Indian pharma companies have reached a mutual settlement with Bristol Myers Squibb in connection with a patent dispute over BMS' oral anticoagulant drug apixaban, even as the Delhi High Court has dismissed BMS' another request for an injunction against Zee Laboratories. 2 May 2023
Pharmaceutical
Russians have significantly increased drugs purchases from other countries amid the ever-declining domestic range and the ever-growing isolation of the country in the international arena, reports The Pharma Letter’s local correspondent. 2 May 2023
Pharmaceutical
As a next step in focusing on the US market, the board of Swedish diagnostic testing and precision medicines firm Immunovia AB has decided to appoint Jeff Borcherding, until now president of Immunovia’s US operation, as global chief executive 2 May 2023
Pharmaceutical
Members of the Russian Parliament have not ruled out the possibility of the beginning forced transfer of licenses for the production of innovative drugs in Russia in case of exodus of their producers from the local market. 2 May 2023
Pharmaceutical
Big pharma financials dominated the news last week, first among which were from Swiss pharma giant Novartis, whose first-quarter 2023 figures beat Wall Street expectations. Also, GSK released results, along with a promise to strengthen its pipeline. On the research front, Ionis and partner AstraZeneca reported positive Phase III data on their eplontersen in the treatment of polyneuropathy. Meantime, Nektar revealed that Eli Lilly had returned rights to the Lupus treatment rezpegaldesleukin (rezpeg). 30 April 2023
Pharmaceutical
As senior figures from the UK biopharma industry gathered in a gloomy London for the Annual Conference of The Association of the British Pharmaceutical Industry (ABPI), many speakers and panellists showed a stoic positivity despite the myriad of challenges engulfing the sector. 28 April 2023
Pharmaceutical
Bipartisan US Senators Michael Bennet and Todd Young and Representative Scott Peters have reintroduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, which would commit $6 billion to reinvigorate innovation in much needed R&D of new antimicrobials. 28 April 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze